JP2012067110A5 - - Google Patents

Download PDF

Info

Publication number
JP2012067110A5
JP2012067110A5 JP2011233850A JP2011233850A JP2012067110A5 JP 2012067110 A5 JP2012067110 A5 JP 2012067110A5 JP 2011233850 A JP2011233850 A JP 2011233850A JP 2011233850 A JP2011233850 A JP 2011233850A JP 2012067110 A5 JP2012067110 A5 JP 2012067110A5
Authority
JP
Japan
Prior art keywords
use according
chlorite
disorder
tcdo
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011233850A
Other languages
English (en)
Japanese (ja)
Other versions
JP5797083B2 (ja
JP2012067110A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012067110A publication Critical patent/JP2012067110A/ja
Publication of JP2012067110A5 publication Critical patent/JP2012067110A5/ja
Application granted granted Critical
Publication of JP5797083B2 publication Critical patent/JP5797083B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011233850A 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸 Expired - Lifetime JP5797083B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54157604P 2004-02-03 2004-02-03
US60/541,576 2004-02-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006552151A Division JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015118841A Division JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Publications (3)

Publication Number Publication Date
JP2012067110A JP2012067110A (ja) 2012-04-05
JP2012067110A5 true JP2012067110A5 (https=) 2013-04-04
JP5797083B2 JP5797083B2 (ja) 2015-10-21

Family

ID=34860199

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸
JP2011233850A Expired - Lifetime JP5797083B2 (ja) 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Country Status (7)

Country Link
US (5) US7105183B2 (https=)
EP (2) EP1711191B1 (https=)
JP (3) JP5072367B2 (https=)
CN (2) CN101102781B (https=)
AU (1) AU2005213300B2 (https=)
CA (2) CA2554511C (https=)
WO (1) WO2005076819A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005510524A (ja) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
EP1810030A1 (en) * 2004-07-16 2007-07-25 Gyros Patent Ab Sequential method
KR101637140B1 (ko) 2005-05-09 2016-07-06 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
CA2617637C (en) * 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
JP5371443B2 (ja) 2005-12-22 2013-12-18 ニューラルタス ファーマシューティカルズ，インコーポレイテッド 亜塩素酸塩製剤、およびこの調製の方法と利用
AU2013234421B2 (en) * 2005-12-22 2015-08-27 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
EP2285409B1 (en) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
BR112012002333A2 (pt) * 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
EP3859746B1 (en) 2009-10-19 2024-10-16 Labrador Diagnostics LLC Integrated health data capture and analysis system
WO2011111043A1 (en) * 2010-03-10 2011-09-15 Yeda Research And Development Co. Ltd Cellular blood markers for early diagnosis of als and for als progression
EP2582391B1 (en) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
PL2605771T3 (pl) * 2010-08-16 2018-10-31 Allergan, Inc. Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
WO2013093891A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP3142674A4 (en) * 2014-05-16 2018-01-17 Neuraltus Pharmaceuticals, Inc. Methods and compositions for treatment of macrophage-related disorders
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
WO2017079161A2 (en) 2015-11-02 2017-05-11 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
EP4412624A4 (en) 2021-10-04 2025-08-20 Neuvivo Inc TREATMENT METHODS FOR ALS PATIENTS
GB2637227A (en) * 2022-05-19 2025-07-16 Neuvivo Inc Biomarkers for neurogenerative disease
WO2025014800A2 (en) * 2023-07-07 2025-01-16 The Regents Of The University Of California Chlorite uses for stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213389A1 (de) * 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
DE3515745A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US5051414A (en) * 1989-08-03 1991-09-24 Dupont Merck Pharmaceutical Company Inhibition of HIV and other retroviruses by polyoxoanions
DE4208828A1 (de) * 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) * 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
WO1999017787A2 (en) * 1997-10-06 1999-04-15 Oxo Chemie Ag Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2001078775A (ja) * 1999-09-14 2001-03-27 Kokuritsu Seishin Shinkei Center マクロファージ機能調節剤
WO2001040517A2 (en) * 1999-11-30 2001-06-07 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
US6685754B2 (en) 2001-03-06 2004-02-03 Alchemix Corporation Method for the production of hydrogen-containing gaseous mixtures
JP2005510524A (ja) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Similar Documents

Publication Publication Date Title
JP2012067110A5 (https=)
JP2013525444A5 (https=)
JP2012092110A5 (https=)
JP2014515013A5 (https=)
JP2015525757A5 (https=)
JP2013509429A5 (https=)
JP2013014622A5 (https=)
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
JP2014515737A5 (https=)
JP2014507446A5 (https=)
JP2014507482A5 (https=)
BR112014000268A2 (pt) pirazolopiridinas com substituinte heteroarilo e utilização destas
AR094202A1 (es) Productos para el cuidado oral que contienen un complejo de zinc tetrabasico-acido amino-haluro, metodo
JP2011102304A5 (https=)
JP2012193216A5 (https=)
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
JP2014530840A5 (https=)
JP2013507408A5 (https=)
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BR112015025675A2 (pt) derivados do tipo bisamida de ácido dicarboxílico, uso dos mesmos, composição farmacêutica à base dos mesmos, e métodos para produzir derivados do tipo bisamida de ácido dicarboxílico
JP2017002035A5 (https=)
JP2015516419A5 (https=)
JP2016521684A5 (https=)
JP2013533867A5 (https=)
JP2017505809A5 (https=)